These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38188199)
61. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. Smith SM; Desai RA; Walsh MG; Nilles EK; Shaw K; Smith M; Chamberlain AM; Derington CG; Bress AP; Chuang CH; Ford DE; Taylor BW; Chandaka S; Patel LP; McClay J; Priest E; Fuloria J; Doshi K; Ahmad FS; Viera AJ; Faulkner M; O'Brien EC; Pletcher MJ; Cooper-DeHoff RM Am Heart J Plus; 2022 Jan; 13():100112. PubMed ID: 35252907 [TBL] [Abstract][Full Text] [Related]
62. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. Vijan SG J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392 [TBL] [Abstract][Full Text] [Related]
63. Association between Premorbid Renin-Angiotensin-Aldosterone System Blockade and the Risk of Acute Kidney Injury in Critically Ill Patients. Chou RH; Yang SF; Wu CH; Tsai YL; Lu YW; Guo JY; Huang PH; Lin SJ Acta Cardiol Sin; 2023 Sep; 39(5):709-719. PubMed ID: 37720403 [TBL] [Abstract][Full Text] [Related]
64. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Al-Mallah M; Khawaja O; Sinno M; Alzohaili O; Samra AB Cardiol J; 2010; 17(5):448-56. PubMed ID: 20865674 [TBL] [Abstract][Full Text] [Related]
65. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury. Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N; JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153 [TBL] [Abstract][Full Text] [Related]
66. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study. Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315 [TBL] [Abstract][Full Text] [Related]
67. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. González-Cambeiro MC; López-López A; Abu-Assi E; Raposeiras-Roubín S; Peña-Gil C; García-Acuña J; González-Juanatey R Rev Port Cardiol; 2016 Dec; 35(12):645-653. PubMed ID: 27865680 [TBL] [Abstract][Full Text] [Related]
68. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349 [TBL] [Abstract][Full Text] [Related]
69. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Sadjadi SA; McMillan JI; Jaipaul N; Blakely P; Hline SS Ther Clin Risk Manag; 2009 Jun; 5(3):547-52. PubMed ID: 19707264 [TBL] [Abstract][Full Text] [Related]
70. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911 [TBL] [Abstract][Full Text] [Related]
71. Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis. Mohammad Z; Ahmad J; Sultan A; Penagaluri A; Morin D; Dominic P J Cardiovasc Electrophysiol; 2023 Apr; 34(4):1037-1042. PubMed ID: 36871177 [TBL] [Abstract][Full Text] [Related]
72. Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cryoballoon ablation outcomes for paroxysmal atrial fibrillation. Al-Seykal I; Bose A; Chevli PA; Hashmath Z; Sharma N; Mishra AK; Laidlaw D World J Cardiol; 2022 Oct; 14(10):537-545. PubMed ID: 36339889 [TBL] [Abstract][Full Text] [Related]
73. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts. Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840 [TBL] [Abstract][Full Text] [Related]
74. Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study. Nardone B; Majewski S; Kim AS; Kiguradze T; Martinez-Escala EM; Friedland R; Amin A; Laumann AE; Edwards BJ; Rademaker AW; Martini MC; West DP Drug Saf; 2017 Mar; 40(3):249-255. PubMed ID: 27943160 [TBL] [Abstract][Full Text] [Related]
75. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review. Mackey K; King VJ; Gurley S; Kiefer M; Liederbauer E; Vela K; Sonnen P; Kansagara D Ann Intern Med; 2020 Aug; 173(3):195-203. PubMed ID: 32422062 [TBL] [Abstract][Full Text] [Related]
76. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. Powers B; Greene L; Balfe LM J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101 [TBL] [Abstract][Full Text] [Related]
77. Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis. Hu Y; Liang L; Liu S; Kung JY; Banh HL J Clin Hypertens (Greenwich); 2023 Aug; 25(8):661-688. PubMed ID: 37417783 [TBL] [Abstract][Full Text] [Related]
78. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis. Al Khalaf MM; Thalib L; Doi SA Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130 [TBL] [Abstract][Full Text] [Related]
79. The effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on progression of gastric cancer: systematic review and meta-analysis. Mehrdad SA; Mirzavi F; Seyedi SMR; Asoodeh A Anticancer Drugs; 2022 Nov; 33(10):983-988. PubMed ID: 35946519 [TBL] [Abstract][Full Text] [Related]
80. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period. Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]